

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

ΚΩΝΣΤΑΝΤΙΝΟΣ ΔΗΜΑΣ

Καθηγητής & Διευθυντής

ΕΡΓΑΣΤΗΡΙΟ ΦΑΡΜΑΚΟΛΟΓΙΑΣ, ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ, ΣΧΟΛΗ
ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ, ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ

ΛΑΡΙΣΑ, Φεβρουάριος 2024

Βιογραφικό Σημείωμα

Όνομα	Θέση		
Κωνσταντίνος Δήμας	Καθηγητής/Διευθυντής		
eRA COMMONS USERNAME	Εργαστήριο Φαρμακολογίας, Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας, Ελλάδα		
Πτυχία/Εκπαίδευση			
Εκπαιδευτικά Ιδρύματα	Δίπλωμα	Έτος	Επιστημονικό Πεδίο
Τμήμα Βιολογίας, ΕΚΠΑ, Αθήνα, Ελλάδα	Πτυχίο	1991	Βιολογία
Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Πανεπιστήμιο Ιωαννίνων, Ιωάννινα, Ελλάδα	Διδακτορικό	1999	Φαρμακολογία

Συνοπτική παρουσίαση

Ο Δρ Κωνσταντίνος Δήμας είναι Καθηγητής και Διευθυντής στο Εργαστήριο Φαρμακολογίας της Ιατρικής Σχολής του Πανεπιστημίου Θεσσαλίας (ΠΘ). Πριν από το διορισμό του στο Πανεπιστήμιο Θεσσαλίας, ήταν ερευνητής στο Εργαστήριο Φαρμακολογίας-Φαρμακευτικής τεχνολογίας του Ιδρύματος Βιοϊατρικών Ερευνών της Ακαδημίας Αθηνών (ΙΙΒΕΑΑ). Έλαβε υποτροφία STA (Special Training Award) από τον Διεθνή Οργανισμό Έρευνας για τον Καρκίνο (IARC), μέλος του Παγκόσμιου Οργανισμού Υγείας (ΠΟΥ), η οποία του επέτρεψε να ενταχθεί στη Μονάδα Μοριακής Καρκινογένεσης του Οργανισμού από τον Οκτώβριο του 2001 έως τον Δεκέμβριο του 2002. Έχει συνεργαστεί και εξακολουθεί να συνεργάζεται με πολλά πανεπιστήμια και ερευνητικά ινστιτούτα, με πιο πρόσφατο το Εθνικό Ινστιτούτο Καρκίνου (NCI, NIH, ΗΠΑ), καθώς και με εταιρείες βιοτεχνολογίας στην Ελλάδα και το εξωτερικό. Συμμετέχει ενεργά σε πολλές προπτυχιακές, μεταπτυχιακές και διδακτορικές διατριβές. Έχει επίσης υπάρξει μέλος της επιστημονικής/καθοδηγητικής επιτροπής ή προσκεκλημένος ομιλητής σε πολλά ελληνικά και διεθνή επιστημονικά συνέδρια. Είναι συγγραφέας ή συν-συγγραφέας >110 εργασιών δημοσιευμένων σε διεθνή περιοδικά με κριτές στον τομέα της φαρμακολογίας και του καρκίνου, περισσότερων από 10 κεφαλαίων βιβλίων και 5 διπλωμάτων ευρεσιτεχνίας με περισσότερες από 3400 αναφορές και h-index 35 (Scopus, πρόσβαση Νοέμβριος 2023). Έχει λάβει ερευνητικές επιχορηγήσεις ύψους άνω των 600000€, είναι μέλος πολλών επιστημονικών εταιρειών όπως η EACR, η Ελληνική Εταιρεία Βασικής και Κλινικής Φαρμακολογίας, η EACPT, μέλος της συντακτικής επιτροπής και κριτής πολλών έγκριτων διεθνών επιστημονικών περιοδικών (Science Advances, Scientific Reports, Molecular Oncology, Biochem. Pharm., Int. J. of Cancer, JPET, Cancer Research, Carcinogenesis, Biomedicines, Cancers, Medicina κ.λπ.) Έχει συμμετάσχει σε επιτροπές αξιολόγησης ερευνητικών έργων για τη GET, το UICC και το Κροατικό Επιστημονικό Ίδρυμα. Τα ερευνητικά του ενδιαφέροντα επικεντρώνονται στη μελέτη και ανάπτυξη νέων αντικαρκινικών φαρμάκων, κυρίως από φυσικές πηγές (π.χ. φυτικά παράγωγα), στη μελέτη νέων αναστολέων της ριβοσωμικής S6 κινάσης p90, στην ανάπτυξη νέων ανταγωνιστών του υποδοχέα σίγμα ως πιθανών στοχευμένων θεραπειών για τον καρκίνο και, τέλος, στην ανάπτυξη νέων βελτιωμένων ζωικών προτύπων καρκίνου (κυρίως ανθρώπινα ξενομοσχεύματα σε ανοσοκατεσταλμένα ποντίκια).

Synopsis

Dr Konstantinos Dimas is Professor and Director of the Laboratory of Pharmacology at the Medical School of the University of Thessaly (UTH). Before his appointment at the University of Thessaly, he was a researcher at the Laboratory of Pharmacology-Pharmaceutical technology of the Biomedical Research Foundation of the Academy of Athens (BRFAA). He received an STA (Special Training Award) fellowship from the International Agency for Research on Cancer (IARC), a member of the World Health Organization (WHO), which allowed him to join the Molecular Carcinogenesis Unit of the Organization from October 2001 to December 2002. He has collaborated and continues to collaborate with many universities and research institutes, most recently with the National Cancer Institute (NCI, NIH, USA), as well as with biotechnology companies in Greece and abroad. He is actively involved in many undergraduate, postgraduate, and PhD theses. He has also been a member of the scientific/steering committee and invited speaker in many Greek and international scientific conferences. He is the author or co-author of >110 papers published in peer-reviewed international journals in the field of pharmacology and cancer, more than 10 book chapters and 5 patents with more than 3400 citations and h-index 35 (Scopus, accessed November 2023). He has received research grants of more than 600000€, is a member of several scientific societies such as EACR, Hellenic Society of Basic and Clinical Pharmacology, EACPT, member of the editorial board and reviewer of several prestigious international scientific journals (Science Advances, Scientific Reports, Molecular Oncology, Biochem. Pharm., Int. J. of Cancer, JPET, Cancer Research, Carcinogenesis, Biomedicines, Cancers, Medicina etc.). He has participated in research project evaluation committees for GET, UICC and Croatian Science Foundation. His research interests focus on the study and development of new anti-cancer drugs, mainly from natural sources (e.g., plant derivatives), the study of new inhibitors of ribosomal S6 kinase p90, the development of new sigma receptor antagonists as potential targeted cancer therapies and finally the development of new improved animal cancer models (mainly human xenografts in immunocompromised mice).

Ενδεικτικά στοιχεία του Βιογραφικού

Ακαδημαϊκές θέσεις/Προϋπηρεσία.

- Φεβρουάριος 2023: Διευθυντής Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας
- 2022-σήμερα: Καθηγητής, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας
- 2018-Μάιος 2022: Αναπληρωτής Καθηγητής, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας
- Μαρ. 2019-Αυγ. 2019: Επισκέπτης Επιστήμονας (Visiting Scientist, Sabbatical), Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, NIH, USA
- Φεβ. 2014 -Αύγ. 2014: Επισκέπτης Επιστήμονας (Visiting Scientist, Sabbatical), Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, NIH, USA
- 2013- 2018: Επίκουρος Καθηγητής, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας
- 2011- 2013: Λέκτορας, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας
- 2003-2011: Ερευνητής Δ, Εργαστήριο Φαρμακολογίας-Φαρμακοτεχνολογίας, Ίδρυμα Ιατροβιολογικών Ερευνών, Ακαδημίας Αθηνών
- 2007-2011: Επιστημονικός Συνεργάτης, Εργαστήριο Φαρμακολογίας Τμήμα Ιατρικής, Σχολή Επιστημών Υγείας, Πανεπιστήμιο Θεσσαλίας
- 2001-2002: Μεταδιδακτορικός ερευνητής, Μονάδα Μοριακής Καρκινογένεσης, IARC, Lyon, France
- 2000-2001: Μεταδιδακτορικός ερευνητής, Τμήμα Κυτταρικής Βιολογίας και Βιοχημείας, Εργαστήριο Νευροανάπτυξης, Ινστιτούτο Παστέρ, Αθήνα
- 1999-2004: Επιστημονικός Συνεργάτης, International Institute of Anticancer Research-IIAR, Καπανδρίτι, Ελλάδα.
- 1995-1996: Τμήμα Βιοχημείας, Γ. Παπανικολάου, Κέντρο Πειραματικής Ογκολογίας, Αθήνα,
- 1994-1999: Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Πανεπιστήμιο Ιωαννίνων, Ιωάννινα, Ελλάδα
- 1991-1994: Τμήμα Ανοσολογίας/Ιστοσυμβατότητας, Ελληνικό Αντικαρκινικό Ινστιτούτο, Αθήνα.

Βραβεία/διακρίσεις

- 2001-2003: WHO post-doctoral fellow (STA, Special Training Award), Unit of Molecular Carcinogenesis, IARC, Lyon, France.

Best poster award

1. Λαφαζάνης Κ, Μπέγας Η, Παπαποστόλου Ι, **Δήμας Κ**. Φαρμακοκινητική μελέτη του αντικαρκινικού φαρμάκου γεμισιταβίνη στον μυ: διερεύνηση των διαφορών μεταξύ υποδόριας και ενδοπεριτοναϊκής οδών χορήγησης. 19^ο Πανελλήνιο Συνέδριο Κλινικής Χημείας, 4-6 Νοεμβρίου 2021, Αθήνα.

2. Sereti E, Tsimplouli C, Karagiannelou T, Tsezou A, Sakellaridis N, **Dimas K**. Sigma Receptors [sRs]: Study of their role in cancer and the development of new targeted anticancer therapies. Abstract book: page 37 (P22). 2016, 1st Training School, COST ACTION CM1407, Belgrade, Serbia.
3. Armutak E, Aydinlik S, Uvez A, Ari F, Sonmez K, Burak Esener OB, Alkan FU, Aktas A, Zeybek US, Ulukaya E, **Dimas K**, Curevin EG. In vitro and in vivo evaluation of the effects of doxorubicin and chloroquine combination on mice Ehrlich ascites carcinoma (EAC). 2016, 6th Multidisciplinary Cancer Research Congress, Konya, Turkey.

Best oral presentation

4. Sereti E, Magouliotis D, Karagianellou T, Sakellaridis N, Zacharoulis D, **Dimas K**. Development of Pancreatic Ductal Adenocarcinoma (PDAC) patient-derived xenografts as platforms for novel therapeutic approaches. 31^o Πανελλήνιο Συνέδριο Χειρουργικής και Χειρουργικό Φορουν 2018 με διεθνή συμμετοχή. 21-24 Νοεμβρίου 2018, Αθήνα
5. Cevatemre B, Erkisa M, Aztopal N, Karakas D, Alper P, Tsimplouli C, Sereti E, **Dimas K**, Ikitimur Armutak EI, Gurel Gurevin E, Uvez A, Mori M, Berardozi S, Ingallina C, Botta B, Ulukaya E. The Plant-Derived Triterpenoid Pristimerin is a Potent Anticancer Agent Due to Its Cytotoxic Activity on Breast Cancer in vitro and in vivo. Abstract book: Page 50 (S-005). 2016, 6th Multidisciplinary Cancer Research Congress, Konya, Turkey.
6. Tsimplouli C, Mahaira L, Rassidakis G, Demetzos C, Hadzopoulou-Cladaras M, Pantazis P, **Dimas K**. Induction of apoptosis and tumor growth delay to a human colon cancer xenograft via a mechanism involving ribosomal p90 S6 kinase (RSK). 2009, 1st International Conference on Molecular Cancer Research, Hellenic Association for Molecular Cancer Research, Athens, Greece.

Travel award

7. Sereti E, Tsimplouli C, Karagianellou T, Sakellaridis N, **Dimas K**. Sigma Receptors: Their role in cancer and the development of targeted therapies for the treatment of pancreatic cancer using Patient Derived Xenograft (PDX) models EACR 25 (25TH Biennial Congress of the European Association for Cancer Research). 30 Jun - 03 Jul 2018, Amsterdam, NL

Selected for oral presentation.

8. **Dimas K**, Mitakou S, Demetzos K, Skaltsounis L, Perez S, Kokkinopoulos D. Cytotoxic activity of diterpenes from the resin ladano of Cistus creticus. 2nd Xenobiotic metabolism and toxicity workshop of Balkan countries, Ioannina, Greece, 1995.

Μετεκπαιδεύσεις/ Σεμινάρια

- [1] 2020: e-Learning Course on Recognition of species-specific pain, suffering and distress – Rats and mice. ΕΛΓΟ-ΔΗΜΗΤΡΑ/EUROPEAN COMMISSION
- [2] 2018-2019: Principles of Clinical Pharmacology (Office of Clinical Research, NIH, USA)
- [3] 2019: Animal Exposure Program (online course, NCI-Frederick training portal, NIH, USA)
- [4] 2019: Laboratory Hazardous Waste training (online course, NCI-Frederick training portal, NIH, USA)
- [5] 2014, 2016: NIH Information Security and Privacy Awareness (online course, NIH, USA)
- [6] 2015, 2019: ACUC training (online course, NCI-Frederick training portal, NIH, USA)

- [7] 2014, 2015: Animal exposure hazard assessment (online course, NCI-Frederick training portal, NIH, USA)
- [8] 2014: Endnote Quick Start (Scientific Library training class, NCI-Frederick training portal, NIH, USA)
- [9] 2014: Mouse Workshop (Office of Animal Care and Use, NIH, USA)
- [10] 2014: Guidelines for Animal Users (Office of Animal Care and Use, NIH, USA)
- [11] 2014: NIH Research Ethics Orientation (online course, NIH, USA)
- [12] 2014: Bloodborne Pathogens Training (*Environment, Health and Safety Program*, Leidos Biomedical Res., Inc, NCI-Frederick, USA)
- [13] 2008: 1st European Course of in Vivo preclinical assays in cancer therapy (Paris, France)
- [14] 1992: F.E.B.S. Immunology Summer School (Ionian Village, Greece)
- [15] 1991: Twenty-five Years of Immunoenzymatic techniques (Athens, Greece)

Επιστημονικές ανακοινώσεις σε συνέδρια με κριτές (κατά χρονολογική σειρά)

- 1) D. Alexopoulou, F. Koutsougianni, G. Kotsopoulos, T. Polychronis, C. Masoura, K. Lafazanis, I. Papathanasiou, V. Trachana, **K. Dimas**. The PDK-1 inhibitor GSK2334470 induces cell death and G1 cell cycle arrest in human pancreatic cancer cells. 6th CONGRESS OF SDIR with international participation "From Collaboration to innovation in Cancer Research" October 2 – 4th 2023 in Belgrade, Serbia. *Selected for oral presentation*.
- 2) D. Alexopoulou, K. Lafazanis, F. Koutsougianni, K. Dimas. *In vitro* anticancer activity of kaempferol-derived flavonoids against pancreatic adenocarcinoma. 6th CONGRESS OF SDIR with international participation "From Collaboration to innovation in Cancer Research" October 2 – 4th 2023 in Belgrade, Serbia. *Selected for oral presentation*.
- 3) hetIL-15 decreases tumor cell dissemination and colonization and synergizes with chemotherapy and surgery to cure murine 4T1 breast tumors. V. Stravokefalou, D. Stellas, S. Karaliota, B. Myers, C. Bergamaschi, K. Dimas, B. Felber, G. Pavlakis. Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA)
- 4) E. Sereti, C. Tsimplouli, M. Pešić, J. Dinić, A. Divac Rankov, E. Armutak, A. Uvez, N. Sakellaridis, **K. Dimas**. Sigma-2 receptor agonist, siramesine, as a potential compound for the treatment of pancreatic cancer. ACR 2021 Virtual Congress: Innovative Cancer Science
- 5) E. Sereti, C. Tsimplouli, E. Kalaitidou, I. Papapostolou, N. Sakellaridis, **K. Dimas**. Study of the Relationship between Sigma Receptor Expression Levels and Some Common Sigma Ligand Activity in Cancer Using Human Cancer Cell Lines of the NCI-60 Cell Line Panel. EACR 2021 Virtual Congress: Innovative Cancer Science.
- 6) E. Sereti, F. Koutsougianni, C. Tsimplouli, M. Pešić, J. Dinić, A. Divac Rankov, E. Armutak, A. Uvez, K. Papaparaskeva, C. Dervenis, N. Sakellaridis, **K. Dimas**. Siramesine, a non-opioid σ_2 receptor agonist as a potential agent for the development of novel targeted treatments for pancreatic cancer. 5th Congress of the Serbian association for cancer research, virtual event, 2021.

- 7) I Papapostolou , E Sereti, E Bouloutsou , V Konteles , F Koutsougianni, A Lambrianidou , A Poultsidi, M Ioannou, A Tsezou, **K Dimas**. A novel triple negative lipid rich breast cancer (TN/LRBC) patient derived xenograft (PDX). 5th Congress of the Serbian association for cancer research, virtual event, 2021.
- 8) K Lafazanis, E. Begas, N. Sakellaridis, H Iatrou and K. Dimas. Development and validation of a simple and reliable UV-coupled HPLC assay for the determination of gemcitabine in serum: application in pharmacokinetic analysis. 5th Congress of the Serbian association for cancer research, virtual event, 2021.
- 9) Κ Λαφαζάνης, Η. Μπέγας, Ι. Παπαποστόλου. **Κ. Δήμας**. Φαρμακοκινητική μελέτη του αντικαρκινικού φαρμάκου γεμισταβίνη στον μυ: διερεύνηση των διαφορών μεταξύ υποδόριας και ενδοπεριτοναϊκής οδών χορήγησης. 19^ο Πανελλήνιο Συνέδριο Κλινικής Χημείας, 4-6 Νοεμβρίου 2021, Αθήνα
- 10) I Papapostolou, E Sereti, E Bouloutsou , V Konteles , F Koutsougianni, A Lambrianidou , A Poultsidi, M Ioannou, A Tsezou, **K Dimas**. Development and characterization of a novel triple negative lipid rich breast cancer (TN/LRBC) patient derived xenograft. 9th International Multithematic Bio-Medical Congress (IMBMC) 18-20 November 2021, Nicosia, Cyprus.
- 11) D. Magouliotis, M. Fergadi, N. Sakellaridis, **K. Dimas**, E. Tatsios, D. Zacharoulis. Development of Pancreatic Ductal Adenocarcinoma (PDAC) Patient Derived Xenografts and Characterization of Aquaporin 7 Expression. 14th Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), 15-17 September 2021, Bilbao. Virtual Congress.
- 12) D Magouliotis, **K Dimas**, N Sakellaridis, M Fergadi, D Symeonidis, D Zacharoulis. In silico investigation and functional enrichment analysis of the human major intrinsic proteins and voltage-gated chloride channel proteins reveal eleven prognostic biomarkers for pancreatic cancer. 14th World Congress of the International Hepato-Pancreato-Biliary Association, 27-29 November 2020, Virtual Congress.
- 13) D Stellas, V Stravokefalou, S Karaliota, B Nagy, S Koslov, **K Dimas**, BK Felber, GN Pavlakis. Combination of hetIL-15 with chemotherapy in triple negative breast and pancreatic cancer mouse models increases tumor necrosis and alleviates metastatic disease. AACR Annual Meeting 2020; April 27-28, 2020, and June 22-24, 2020; Philadelphia, PA, USA [Cancer Research 80 (16 Supplement), 6651-6651].
- 14) GN Pavlakis, C. Bergamaschi, D Stellas, S Karaliota, B Nagy, V Stravokefalou, **K Dimas**, S Jensen, BA Fox and BK Felber. Mechanism of Heterodimeric IL-15 in tumor reduction: Induction of myeloid-lymphoid cell interactions leads to IFN- γ dependent lymphocyte recruitment by dendritic cells into tumors. IMMUNOLOGY 2020, May 8 – 12 in Honolulu, Hawai’I, USA [The Journal of Immunology 204 (1 Supplement), 90.13-90.13].
- 15) S Liliopoulos, G Stavrakakis, **K Dimas**. development of a mathematical model that may predict the activity of potential anticancer agents in a pancreatic ductal adenocarcinoma (PDAC) xenograft. 11th Conference of Hellenic Pharmacology Association, 2-4 October 2020, Alexandroupolis, Greece.
- 16) E Sereti, C Tsimplouli, E Kalaitidou, N Sakellaridis, **K Dimas**. Study of the relationship between sigma receptors levels and some common sigma ligands activity in cancer using human cancer cell lines of the NCI-60 cell line panel. 11th Conference of Hellenic Pharmacology Association, 2-4 October 2020, Alexandroupolis, Greece.
- 17) K Lafazanis, E Begas, IPapapostolou, **K Dimas**. Development of a simple and inexpensive method for the study of gemcitabine levels in rat serum using an improved reversed – phase HPLC assay coupled to UV detection. 11th Conference of Hellenic Pharmacology Association, 2-4 October 2020, Alexandroupolis, Greece.

- 18) E Sereti, F Koutsougianni, P Grammatikou, C Dervenis, D Zacharoulis, M Pešić, J Dinic, AR Divac, E Ilkay-Armutak, A Üvez, **K Dimas**. Siramesine, a sigma-2 receptor agonist induces cell death *via* induction of both apoptosis and autophagy in a patient derived PDAC model *in vitro* and *in vivo*. 11th Conference of Hellenic Pharmacology Association, 2-4 October 2020, Alexandroupolis, Greece.
- 19) R Özyurt, N Erkasap, M Özkurt, S Erkasap, E Ulukaya, **K Dimas**. The effect of NOTCH, IL-1 and LEPTIN (NILCO) inhibition in xenograft colorectal cancer. 98th Meeting of the German Physiological Society, 30 Sep-1 Oct 2019, Ulm, Germany
- 20) D Magouliotis, G Christodoulidis, V Tasiopoulou, N Sakellaridis, **K Dimas**, D Zacharoulis. Expression profile of the Cadherins (CDHs) gene family in patients with pancreatic cancer. 38th Congress of the European Society of Surgical Oncology, 10-12 October 2018, Budapest, Hungary.
- 21) D Magouliotis, V Tasiopoulou, **K Dimas**, N Sakellaridis, D Zacharoulis. Differential gene expression profile of the aquaporin (AQP) gene family components in pancreatic cancer. 13th World Congress of the International Hepato-Pancreato-Biliary Association, 4-7 September 2018, Geneva, Switzerland.
- 22) D Magouliotis, V Tasiopoulou, **K Dimas**, N Sakellaridis, D Zacharoulis. Transcriptomic analysis of the claudin (CLDN) gene family in pancreatic cancer. 13th World Congress of the International Hepato-Pancreato-Biliary Association, 4-7 September 2018, Geneva, Switzerland.
- 23) D Magouliotis, V Tasiopoulou, **K Dimas**, N Sakellaridis, D Zacharoulis. Gene expression profile of sigma-1 (s1R) and sigma-2 (s2R) receptors in pancreatic cancer. 13th World Congress of the International Hepato-Pancreato-Biliary Association, 4-7 September 2018, Geneva, Switzerland.
- 24) E Sereti, D Magouliotis, T Karagianellou, N Sakellaridis, D Zacharoulis, **K Dimas**. Development of pancreatic ductal adenocarcinoma (PDAC) patient derived xenografts as platforms for novel therapeutic approaches. 13th World Congress of the International Hepato-Pancreato-Biliary Association, 4-7 September 2018, Geneva, Switzerland.
- 25) D Magouliotis, V Tasiopoulou, **K Dimas**, N Sakellaridis, D Zacharoulis. Over-expression of Chloride Intracellular Channels (CLICs) 1 and 3 in pancreatic cancer. 13th World Congress of the International Hepato-Pancreato-Biliary Association, 4-7 September 2018, Geneva, Switzerland.
- 26) E Sereti, C Tsimplouli, B Cevatemre, E Ulukaya, N Sakellaridis, **K Dimas**. PO-213 Sigma receptors: development of novel therapeutic approaches in pancreatic cancer. 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018.
- 27) C. Bergamaschi, **K. Dimas**, B. Nagy, S.M. Jensen, B.A. Fox, B.K. Felber, G.N. Pavlakis. Treatment with heterodimeric IL-15 promotes effector T cell infiltration into several tumor types. 2017, Cytokines, Kasagawa, Japan [Cytokine 100 (2017), 180-181]
- 28) S Aydinlik, E I Ikitimur-Armutak, A Uvez, F Ari, K Sonmez, B Osman, B Esener, F. Ustun-Alkan, A. Aktas, SU Zeybek, E Ulukaya, K Dimas, E Gurel-Gurevin. Chloroquine improves the anticancer effects of doxorubicin in vitro and in vivo models on Mouse Mammary Tumor Ehrlich ascites carcinoma (EAC). 2nd EACR-OECI Conference, 13 - 16 March 2017, Amsterdam, Netherlands
- 29) B. Cevatemre, **K. Dimas**, B. Botta and E Ulukaya. Pristimerin is a Promising Natural Product against Breast Cancer in vitro and in vivo through Apoptosis and the Blockage of Autophagic Flux. 2017, 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey [Proceedings 2017, 1(10), 973; doi:10.3390/proceedings1100973]

- 30) A Podolski-Renic, M Dragoj, S Stojkovic, J Dinic, J Bankovic, E Sereti, S Jovanovic Stojanov, **K Dimas**, M Pesic, T Stankovic. Targeting CXCR4 and FAK in non-small cell lung carcinomas with co-inactivated p53 and PTEN tumor suppressors. 2017, 42nd ESMO Congress (ESMO 2017), Spain. [*Annals of Oncology*, 28 (5), suppl_5, 1 <https://doi.org/10.1093/annonc/mdx390.039>]
- 31) I. Patrikios, A. Yiallouris, C. de ford, N. Fedosova, G. Wolfgang, **K. Dimas**, E. Sereti, and A. Stephanou. *Tripterygium wilfordii promotes selective cell death via a novel Na/K ATP-ase pathway*. 2017, 5ο Διεθνές Πολυθεματικό Επιστημονικό Βιο-Ιατρικό Συνέδριο, Κύπρος.
- 32) I. Patrikios, A. Yiallouris, C. de ford, N. Fedosova, G. Wolfgang, **K. Dimas**, E. Sereti, K. Socratous, and A. Stephanou. *Amygdalin extract promotes selective cell death*. 2017, 5ο Διεθνές Πολυθεματικό Επιστημονικό Βιο-Ιατρικό Συνέδριο, Κύπρος.
- 33) A. Yiallouris, I. Patrikios, E. O. Johnson, K. **Dimas**, E. Sereti, C. de ford, N. Fedosova, G. Wolfgang, K. Socratous, A. Stephanou. *Annonasin from Graviola extract promotes selective cancer cell death in vitro and in vivo via NKA and SERCA downregulation pathway*. 2017, 5ο Διεθνές Πολυθεματικό Επιστημονικό Βιο-Ιατρικό Συνέδριο, Κύπρος.
- 34) E. Sereti, C. Tsimplouli, T. Karagiannelou, A. Tsezou, N. Sakellaridis, **K. Dimas**. Sigma Receptors [sRs]: Study of their role in cancer and the development of new targeted anticancer therapies. Abstract book: page 37 (P22). 2016, 1st Training School, COST ACTION CM1407, Belgrade, Serbia.
- 35) Ikitimur Armutak E.I., Aydinlik S., Uvez A., Ari F., Sonmez K., Esener O., Behzat B., Ustun A. F., Aktas A., Zeybek S. U., Ulukaya E., **Dimas K**, Gurel G. An in vitro and in vivo evaluation of the effects of doxorubicin and chloroquine combination on mice ehrlich ascites carcinoma (EAC). 2016, 6th Multidisciplinary Cancer Research Congress, Konya, Turkey.
- 36) B. Cevatemre, M. Erkisa, N. Aztopal, Didem Karakaş, P. Alper, C. Tsimplouli, E. Sereti, **K. Dimas**, E. I. Ikitimur Armutak, E. Gurel Gurevin, A. Uvez, M. Mori, S. Berardozi, C. Ingallina, B. Botta, E. Ulukaya. The Plant-Derived Triterpenoid Pristimerin is a Potent Anticancer Agent Due to Its Cytotoxic Activity on Breast Cancer in vitro and in vivo. Abstract book: Page 50 (S-005). 2016, 6th Multidisciplinary Cancer Research Congress, Konya, Turkey.
- 37) G. N. Pavlakis, S.M. Ng, **K. Dimas**, A. Valentin, B. Nagy, C. Alicea, B. K Felber and C. Bergamaschi. *hetIL-15 therapy results in tumor control by promoting tumor infiltration of CD8+ T cells with increased cytotoxic potential and decreased PD-1 expression*. Immunology 2016. Seattle, WA, USA, [J Immunol May 1, 2016, 196 (1 Supplement) 72.5]
- 38) I. Patrikios, A. Yiallouris, C. de ford, N. Fedosova, G. Wolfgang Graier, **K. Dimas**, E. Sereti, K. Socratous, and A. Stephanou. *Graviola Extract: A non- toxic Compound that Promotes cell death in Cancer Cells*. 2016, 67^ο Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας, Ιωάννινα.
- 39) I. Kotsoni, M. Tsesmelis, C. Tsimplouli, E. Sereti, N. Sakellaridis, A. Tsezou, **K. Dimas**. *Targeting mTOR complexes and ribosomal s6 kinases for the development of novel therapies for thyroid cancer*. 2016, 67^ο Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας, Ιωάννινα.
- 40) Tsimplouli C, Sereti E, Papaparaskeva P, Dervenis C, Zacharoulis D, Karagiannelou T, Tsezou A, Perez S.A, Mahaira G.L, Sakellaridis N, **Dimas K**. *Patient-derived models of human pancreatic cancer in immunocompromised mice for preclinical drug development*. EACR-Sponsored 3d ANTICANCER AGENT-Development Congress. 2015, Izmir, Turkey

- 41) Kamposioras K, Tsimplouli C, Migneco G, Papadopoulos V, Anthoney A, Papandreou C, Sakellaridis N, DelGaldo F, **Dimas K**. *The role of caveolin-1 in aggressiveness and chemo-resistance of pancreatic duct adenocarcinoma*. EACR-Sponsored 3d ANTICANCER AGENT- Development Congress. 2015, Izmir, Turkey
- 42) Katsori A-M, Patsilnakos A, **Dimas K**, Ragno R, Hadjipavlou-Litina D. Novel hybrid molecules as possible antiproliferative agents and lipoxygenase inhibitors. 21st National Meeting on Medicinal Chemistry, 2012, Palermo, Italy.
- 43) Ζώρζου Μ, Τσιμπλούλη Χ, Δήμας Κ, Πίππα Ν, **Δεμέτζος Κ**. Παρασκευή λιποσωμάτων με ενσωματωμένη σκλαρεόλη και in vitro φαρμακολογική αξιολόγηση σε καλλιέργειες δυο και τριών διαστάσεων, 1^ο Συνέδριο Φαρμακευτικών Επιστημών, Αθήνα, 2012.
- 44) Ulukaya E, Ari F, Dimas **K**, Ikitimur EI, Guney E, Sakellaridis N, Yilmaz VT. Promising Anti-cancer Activity of a Novel Palladium (II) Complex on Human Breast Cancer Cells in Vitro and in Vivo. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Stockholm, Sweden, Sep 23-27, 2011
- 45) Almeida C, Kehraus S., **Dimas K**, and König GM, Marilines A – D, Novel Phthalimidines from the Sponge-derived Fungus *Stachylidium* sp. International Conference New Biotrends in Green Chemistry, Dortmund, Germany, December 1-2, 2010
- 46) Koliou X, **Dimas K**, Sakellaridis N and Mangoura D. PKCε regulates differentiation in Peripheral Nervous System tumor cells Neuroscience Days of the Hellenic Society for Neuroscience, Athens Greece, 2010
- 47) Tsirmoula S, **Dimas K**, Ravazoula P and Papadimitriou E. Role of pleiotrophin in human prostate cancer cell growth in vivo. 6th Panhellenic Congress of Pharmacology, Heraklion, Crete, Greece 2010
- 48) Dimopoulou Th, Leondaritis G, Rassidakis GZ, Yilmaz VT, Ulukaya E, Guney E, Ari F, Sakellaridis N, **Dimas K**. Establishment and preliminary pharmacological characterization of a primary anaplastic thyroid cancer xenograft model. 61st EEMBB meeting, Alexandroupolis, Greece 2010.
- 49) Mahaira L, Tsimplouli C, Sakellaridis N, Alevizopoulos K, Demetzos C, Han Z, Pantazis P, **Dimas K**. The Induction of apoptosis by labd-14-ene-8,13- diol (Sclareol) and the suppression of tumour growth of human colon cancer cells is p53-independent. 6th Panhellenic Congress of Pharmacology, Heraklion, Crete, Greece 2010
- 50) Katsori AM, **Dimas K**, Trangas T, Vanden Berghe W, Palagani A, Bougarne N, Haegeman G, Hadjipavlou-Litina D. Anticancer, anti-inflammatory, antioxidant and NF-κB inhibition studies of novel 3,5-bis(arylidene)-4-piperidone derivatives. 61st EEMBB meeting, Alexandroupolis, Greece 2010.
- 51) Rassidakis, Z, Tsioli, P, **Dimas, K**, Atsaves, V, Anronoglou, A, Vassilakopoulos, T, Panayiotidis, P, Patsouris, E. Establishment, characterization and pharmacologic evaluation of a unique in vitro and ex vivo study model for B-cell nodal marginal zone lymphoma. 15th Annual Meeting of the European-Hematology-Association, Barcelona, Spain, 2010
- 52) Gardikis K, Tsimplouli C, Hatziantoniou S, **Dimas K**, Bucos M, Zervou M, Skrettas CG, Steele BR, Michas-Screttas M, Demetzos C. Development of new liposomal locked-in dendrimer (Ild) for delivery of anticancer drugs, 2th Interantional Sympsium on Biological Applications of Dendrimers, Perquerolles Island France, 2010.
- 53) Katsori AM, **Dimas K**., Vanden Berghe W., Trangas T., Bougarne N., Haegeman G., Hadjipavlou-Litina D. “Novel heterocyclic 4-piperidone derivatives as possible NF-κB inhibitors with anti-inflammatory and/or anti-cancer activity”. 14th Hellenic Symposium on Medicinal Chemistry, April 23-25, 2010, Thessaloniki, Greece

- 54) Tsimplouli C, Mahaira L, Rassidakis G, **Dimas K**. Anticancer activity of a novel kaempferol glucoside, Tac, is mediated by a mechanism involving RSK inhibition. 21st EACR Conference, Oslo, Finland, 2010.
- 55) Tsimplouli C, Mahaira L, Rassidakis G, **Dimas K**. Induction of apoptosis and tumor growth delay to a human colon cancer xenograft via a mechanism involving ribosomal p90 s6 kinase (rsk). 1st International Conference on Molecular Cancer Research, Athens, Greece, 2009.
- 56) Lagadinou ED, Kokkinou D, Themeli M, **Dimas K**, Spyridonidis A and Zoumbos NC. A low redox state characterizes a distinct subset of blasts with progenitor/" Stem-Like" properties in Acute Myeloid Leukemia. 38th Annual Scientific meeting of ISEH-Society-for-Hematology-and-Stem-Cells, Athens, Greece, 2009.
- 57) Lagadinou ED, Kokkinou D, Themeli M, **Dimas K**, Spyridonidis A and Zoumbos NC. Characterization of distinct leukemic subsets according to their redox state. 19^o Annual Pan-Hellenic Congress of Hematology, Athens, Greece, 2008.
- 58) Pandelidou M, Dimas K, Georgopoulos A, Hatziantoniou S, Demetzos C. Preparation, characterization and in vitro evaluation of liposome-incorporated curcumin on colorectal cancer cell lines A. 13^o Πανελλήνιο συνέδριο φαρμακοχημείας, Αθήνα 2008. B. 5TH Συνέδριο Φαρμακολογίας, Αθήνα, 2008.
- 59) Pantelidou M, **Dimas K**, Georgopoulos A, Hatziantoniou S, Demetzos C. Preparation characterization and in vitro evaluation of liposome-incorporated curcumin on colorectal cancer cell lines International Liposome Society Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, London, UK, 2007.
- 60) Λαγκαδινού ΕΔ, Ζήρος Π, Τσοπρά Ο, **Δήμας Κ**, Θανοπούλου Ε, Καρακάντζα Μ, Πανταζής Π, Σπυριδωνίδης Α και Ζούμπος Ν. Η αδυναμία ενεργοποίησης της c- jun n-terminal kinase (jnk) συνιστά ένα νέο μηχανισμό χημειοαντίστασης στην οξεία μυελογενή λευχαιμία (ΟΜΛ). 18^o Annual Pan-Hellenic Congress of Hematology, 14-17 November, Thessaloniki, Greece, 2007. (Oral Presentation)
- 61) Lagadinou ED, Ziros P, Tsopra O, **Dimas K**, Thanopoulou E, Kouraklis-Symeonidis A, Karakantza M, Pantazis P, Zoumbos NC. Absence of JNK activation is a predictor of anthracycline resistance in AML. 12th Congress of the European Hematology Association, Neue Messe Vienna, June 7-10, Austria, 2007.
- 62) Lagadinou ED, Ziros PG, Tsopra OA, Thanopoulou E, **Dimas K**, Pantazis P, Spyridonidis A and Nicholas C. Zoumbos NC: "c- Jun N-terminal Kinase (JNK) activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia" 49th Annual Meeting of The American Society of Hematology, December 8-11, Atlanta, Georgia, USA, 2007.
- 63) Lagadinou E, Ziros P, Tsopra O, Thanopoulou E, Kouraklis A, Symeonidis A, Karakantza M, Zikos P, **Dimas KS**, Pantazis P, Zoumbos NC. Activation of c-Jun-NH2-Terminal Kinase is implicated in the induction of apoptosis in chemotherapy treated primary AML cells in vitro. 17^o Annual Pan-Hellenic Congress of Hematology, 22-26 November, Athens, Greece 2006 (Oral Presentation)
- 64) Matsingou C, **Dimas K**, Demetzos C. Development of a liposomal formulation of a cytotoxic labdane type diterpene and *in vitro* evaluation, Cell Molecular Biol. Letters, Vol. 10 Supplement, Poland, 2005
- 65) Matsingou C, **Dimas K**, Demetzos C. Incorporation of a cytotoxic labdane type diterpene into dppc and epc liposomes, physicochemical characterization, and in vitro pharmacological evaluation of the final preparation. International Liposome Society Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, London, UK, 2005.
- 66) **Dimas K**, Hatziantoniou S, Tseleni S, Demetzos C et al. Liposomal sclareol induces tumor supressor in colon human cancer (hct116) xenografts. International Liposome Society Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, London, UK, 2005

- 67) Matsingou C, **Dimas K**, Demetzos C. Development of a liposomal formulation of a cytotoxic labdane type diterpene and *in vitro* evaluation. Cell Molecular Biol. Letters, Vol. 10 Supplement, 2005.
- 68) Paradissi A, Hatziantoniou S, Georgopoulos A, Psarra AM, **Dimas K**, Demetzos C. Comparative study of the uptake of free and liposomal sclareol on human colon, lung and breast cancer cell lines. A. 2nd EUFERS Conference on Optimising Drug Delivery and Formulation, Versailles 2005, France. B. International Liposome Society Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, London, UK, 2005.
- 69) Papadaki M, Khan H, Sotiriadou N, Hatziantoniou S, ALEVIZOPOULOS K, Pantazis P, Demetzos C, **Dimas K**. Sclareol induces cell cycle arrest and apoptosis in human colon cancer cells via a p53 independent pathway. 13^o EuroConference in Apoptosis, Budapest, Hungary, 2005.
- 70) Saroglou V, Karioti A, Demetzos C, **Dimas K**, Skaltsa H. Sesquiterpene lactones from *centaurea spinosa* and their antibacterial activity and cytostatic/cytotoxic activity against human cancer cell lines. 12th Greek Pharmaceutical Conference, Athens, 2005.
- 71) Lagadinou ED, **Dimas K**, Tsopra O, Karakantza M, Pantazis P, Zoumbos NC "Absence of JNK activation in anthracycline resistant human leukaemia cells *in vitro*", Experimental Hematology, July 17- 20, New Orleans, USA, 2004 (oral presentation).
- 72) Papagiannaros A, Demetzos C, **Dimas K**, Papaioannou G. *In vitro* cytotoxic activity of doxorubicin-pamam dendrimer complex incorporated into hepc liposomes against cancer cell lines. 7th International Conference of Anticancer Research, Corfu, Greece, 2004.
- 73) Matsingou X, Hatziantoniou S, Georgopoulos A, **Dimas K**, Terzis T, Mavromoustakos. Demetzos C. Encapsulation of labdane type diterpenes into liposomes: physicochemical properties and biological activity against human cancer cell lines. 7th International Conference of Anticancer Research, Corfu, Greece, 2004.
- 74) **Dimas K**, Hatziantoniou S, Georgopoulos A, Pantazis P, Demetzos C. Treatment of human colon cancer xenografts, grown in nod/scid mice, with liposome-encapsulated sclareol. a potential use of labdanes as novel anticancer agents. 7th International Conference of Anticancer Research, Corfu, Greece, 2004.
- 75) Papagiannaros A, Demetzos C, **Dimas K**, Hatziantoniou S, Papaioannou G. Th. Encapsulation of doxorubicin in hexadecylphosphocholine liposomes. Evaluation of their cytostatic/ cytotoxic activity *in vitro*. 6th International conference "liposome advances" London, UK, 2003.
- 76) Saroglou V, Karioti A, **Dimas K**, Demetzos C, Skaltsa H. sesquiterpene lactones from the aerial parts of *Centaurea spinosa* and their cytotoxic/cytostatic activity against human cell lines *in vitro*, 50th Annual Meeting of the Society for Medicinal Plant Res., Spain, 2002.
- 77) Malisiova F, Hatziantoniou S, Demetzos C, **Dimas K**. Lipid analysis of Greek almond oil [*prunus dulcis* (mill.) d.a.webb (syn. *prunus amygdalus*)]. 2nd International Symposium on Medicinal Plants, Chalkidiki, Greece, 2002.
- 78) Koukoulitsa E, Karioti A, **Dimas K**, Demetzos C, Skaltsa H. Sesquiterpene lactones from the aerial parts of *centaurea zuccariana* and their cytotoxic/cytostatic activity against human cell lines *in vitro*. 49th Annual Meeting of the Society for Medicinal Plant Res., Erlangen, Germany, 2001.
- 79) Maswadeh H, Hatziantoniou S, Demetzos C, **Dimas K**, Georgopoulos A, Rallis M. Encapsulation of vinblastine into new liposome formulations prepared from triticum (wheat germ) lipids and its activity against human leukemic cell lines. 10th Greek Pharmaceutical Conference, Athens 2001.

- 80) Maswadeh H, Demetzos C, **Dimas K**, Hatziantoniou S, Georgopoulos A, Rallis P, Dallas M. Accumulation of vinblastine into transferosomes and liposomes in response to a transmembrane ammonium sulfate gradient and their cytotoxic/ cytostatic activity in vitro. 10th Greek Pharmaceutical Conference, Athens 2001.
- 81) **Dimas K**, Sphiniadakis I, Georgopoulos A, Deligannis P and Demetzos C. Comparative study of the cytotoxic effect of Caelyx and free Doxorubicin against human leukemic cell lines. 1st International Jordanian-Greek Medical Congress, Jordan, Amman, 2000.
- 82) Patsavoudi E, Yfanti E, Meintanis S, **Dimas K**, Matsas R and Margaritis L. Changes in cytoskeletal organization of migrating Schwann cells in the presence of monoclonal antibody to the 4C5 antigen. 30th Annual Meeting, Society for Neurosciences, New Orleans, USA, 2000.
- 83) Maswadeh H, Hatziantoniou S, Demetzos C, **Dimas K**, Rallis M, Dallas P. Encapsulation of vinblastine into liposomes prepared from natural sources. GA/ISE-Congress of Planta Medica, Zurich, Switzerland, 2000.
- 84) Yfanti E, **Dimas K**, Meintanis S, Matsas R, Margaritis L and Patsavoudi E. The 4C5 antigen is associated with actin cytoskeletal organization of migrating Schwann cells in vitro. 15th Annual Conference of HSN, Patra 2000.
- 85) **Dimas K**, Mitaku S, Demetzos C, Skaltsounis AL, Perez S, Kokkinopoulos D. Cytotoxic activity of flavonoids from the buds of *Platanus orientalis*. Balkan congress of oncology, Athens, Greece, 1996.
- 86) **Dimas K**, Mitakou S, Demetzos K, Skaltsounis L, Perez S, Kokkinopoulos D. Cytotoxic activity of diterpenes from the resin *ladano* of *Cistus creticus*. 2nd Xenobiotic metabolism and toxicity workshop of Balkan countries, Ioannina, Greece, 1995.
- 87) **Dimas C**, Perez S, Kokkinopoulos D. Preparation of a novel enzyme immunoassay for the measurement of high values of human chorionic gonadotrophin in human serum. 3d International Conference of the Mediterranean Society of tumor marker oncology, Athens, Greece, 1994.
- 88) Sotiriadou R, Kokkinopoulos D, Missitzis J, Ardavanis A, Hatzidou S, **Dimas K**, Perez S. DIK17 antigen: A possible early marker of cancer development. 3d International Conference of the Mediterranean Society of tumor marker oncology, Athens, Greece, 1994.
- 89) Sotiriadou R, Missitzis J, Perez S, **Dimas K**, Papamichail M, Chryssochou MA, Kokkinopoulos D. Expression of DIK17 antigen on the peripheral blood lymphocytes of patients with breast cancer. HSBBCR International Congress, Corfu, Greece, 1993.
- 90) Kokkinopoulos D, **Dimas K**, Perez S, Papamichail M. Development of an ELISA for the measurement of human IgE. 1st Greek Conference of Clinical Allergiology, Athens 1992.
- 91) **Dimas K**, Kokkinopoulos D, Perez S, Papamichail M. Production of monoclonal Abs against hCG and their use for the development of a diagnostic test. 15th Greek Conference of Microbiology, Thessaloniki 1992.
- 92) Kokkinopoulos D, **Dimas K**, Perez S, Papamichail M. Production of monoclonal Abs against hLH and their use for the development of a diagnostic test. 15th Greek Conference of Microbiology, Thessaloniki 1992.
- 93) **Dimas K**, Kokkinopoulos D, Perez S, Papamichail M. Effects of hcg on immunological parameters of normal human PBML. 19th Annual Greek Conference of Medicine, Athens 1993.
- 94) Kokkinopoulos D, Haghefeld B, **Dimas K**, Vidali E, Tsamoura A, Perez S. Development and qualitative control of an ELISA for human ferritin. 6th Greek Conference of Hematology, Kavala 1993.

95) Perez S, **Dimas K**, Demetzos K, Mitakou S, Kokkinopoulos D. Effects of flavonoids on leukemic cell lines, normal resting and PHA-activated PBML 6TH Greek Conference of Hematology, Kavala 1993.

Επιστημονικά άρθρα σε διεθνή περιοδικά με κριτές (με χρονολογική σειρά).

Orcid: https://orcid.org/0000-0001-7481-9148	
h index (Scopus, Author ID:6602667610)	36
Total citations	3500

Πρωτότυπα άρθρα

- [1] Kamposioras K, Dinas PC, Barriuso J, Trachana V, **Dimas K**. Caveolin-1 protein expression as a prognostic biomarker of gastrointestinal tumours: A Systematic Review and Meta-Analysis. Eur J Clin Invest. 2023 Jul 27: e14065. doi: 10.1111/eci.14065.
- [2] Özyurt R, Erkasap N, Özkurt M, Erkasap S, **Dimas K**, Çakir Gündoğdu A, Ulukaya E Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer. Turk J Biol. 2023 Aug 10;47(4):290-300. doi: 10.55730/1300-0152.2663. eCollection 2023.
- [3] Stavroulaki D, Kyroglou I, Skourtis D, Athanasiou V, Thimi P, Sofianopoulou S, Kazaryan D, Fragouli PG, Labrianidou A, **Dimas K**, Patias G, Haddleton DM, Iatrou H. Influence of the Topology of Poly(L-Cysteine) on the Self-Assembly, Encapsulation and Release Profile of Doxorubicin on Dual-Responsive Hybrid Polypeptides. Pharmaceutics. 2023 Feb 27;15(3):790. doi: 10.3390/pharmaceutics15030790.
- [4] Karra AG, Tsialtas I, Kalousi FD, Georgantopoulos A, Sereti E, **Dimas K**, Psarra AMG. Increased Expression of the Mitochondrial Glucocorticoid Receptor Enhances Tumor Aggressiveness in a Mouse Xenograft Model. Int. J. Mol. Sci. 2023, 24(4), 3740; <https://doi.org/10.3390/ijms24043740>
- [5] Stravokefalou V, Stellas D, Karaliota S, Nagy BA, Valentin A, Bergamaschi C, **Dimas K***, Pavlakis GN. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC. Front Immunol. 2023 Jan 13;13: 1014802.doi: 10.3389/fimmu.2022.1014802. eCollection 2022 (*co-corresponding author)
- [6] Özyurt R, Erkasap N, Özkurt M, Erkasap SM, **Dimas K**, Gündoğdu AC, and Ulukaya E. Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer colorectal cancer. Turkish Journal of Biology: Vol. 47: No. 4, doi.org/10.55730/1300-0152.2663
- [7] Magouliotis DE, Karamolegkou AP, Zotos P, Tatsios E, Samara AA, Alexopoulou D, Koutsougianni F, Sakellaris N, Zacharoulis D and **Dimas K**. Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer. Medicina (Kaunas), 2022 Nov 17;58(11): 1663.doi: 10.3390/medicina58111663

- [8] Magouliotis DE, Lafazanis K, Koutsougianni F, Sakellaridis N, Ioannou M, Zacharoulis D and **Dimas K**. Establishment of Patient-derived Orthotopic Xenografts (PDX) as Models for Pancreatic Ductal Adenocarcinoma. *In vivo*, 2022 36(3), pp. 1114–1119. Doi: 10.21873/in vivo.12809
- [9] Chrysostomou V, Katifelis H, Gazouli M, **Dimas K**, Demetzos C, Pispas S. Hydrophilic Random Cationic Copolymers as Polyplex-Formation Vectors for DNA. *Materials (Basel)*. 2022 Apr 4;15(7):2650
- [10] Utkusavas A, Gurel Gurevin E, Yilmazer N, Uvez A, Oztay F, Bulut H, Ustunova S, Esener OBB, Sonmez K, Erol Kutucu D, Meral I, **Dimas K**, Armutak EI. Effects of combined administration of doxorubicin and chloroquine on lung pathology in mice with solid Ehrlich ascites carcinoma. *Biotech Histochem*. 2022 Mar 4;1-12
- [11] Nintou E, Karligioutou E, Vliora M, Fatouros IG, Jamurtas AZ, Sakellaridis N, **Dimas K**, Flouris AD. Effects of In Vitro Muscle Contraction on Thermogenic Protein Levels in Co-Cultured Adipocytes. *Life*. 2021 Nov;11(11)1227.
- [12] Pitsikas N, **Dimas K**. *Crocus sativus* L. Extract and Its Constituents: Chemistry, Pharmacology and Therapeutic Potential. *Molecules*. 2021 Jul 12;26(14):4226. (editorial)
- [13] Naziris N, Pippa N, Sereti E, Chrysostomou V, Kędzierska M, Kajdanek J, Ionov M, Miłowska K, Balcerzak Ł, Garofalo S, Limatola C, Pispas S, **Dimas K**, Bryszewska M, Demetzos C. Chimeric Stimuli-Responsive Liposomes as Nanocarriers for the Delivery of the Anti-Glioma Agent TRAM-34. *Int J Mol Sci*. 2021 Jun 10;22(12):6271
- [14] Dinas PC, Domanovic D, Koutedakis Y, Hadjichristodoulou C, Stefanidis I, Papadopoulou K, **Dimas K**, Perivoliotis K, Tepetes K, Flouris AD. The Presence of Fungal and Parasitic Infections in Substances of Human Origin and Their Transmission via Transfusions and Transplantations: Protocol for Two Systematic Reviews. *JMIR Res Protoc*. 2021 Jun 10;10(6): e25674
- [15] Üvez A, Kiliç S, Esener OB, Ünder D, Saltan FZ, **Dimas K**, İlkey Armutak E. Combinatorial Usage of Sumac Unripened Fruit Extract (*Rhus Coriaria*) and Tannic Acid Enhanced Synergistic Anti-Angiogenic Effect on Chick Chorioallantoic Membrane Assay. *Acta Vet Eurasia* 2021; 47: 2-9
- [16] Lambrianidou A, Sereti E., Soupsana K, Komini C, **Dimas K**. Trangas T. mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival. *Cellular Signalling*, 2021, 80, 109912
- [17] Sereti E., Tsimplouli, C., Kalaitidou, E., Sakellaridis, N., **Dimas, K**. Study of the relationship between sigma receptor expression levels and some common sigma ligand activity in cancer using human cancer cell lines of the nci-60 cell line panel. *Biomedicines*, 2021, 9(1), pp. 1–20, 38 (Invited)
- [18] Liliopoulos SG, Stavrakakis GS, **Dimas K**. Advanced Non-linear Mathematical Model for the Prediction of the Activity of a Putative Anticancer Agent in Human-to-mouse Cancer Xenografts. *Anticancer Res*. 2020 Sep;40(9):5181-5189
- [19] Tsianaka E, Sereti E, Papacharalambous C, Ioannou M, Pitsikas N, Dimoulas A, Sakellaridis N, Fountas K, **Dimas K**. Toxicity study of graphene-coated Poly (methyl methacrylate) membranes on the brain cortex of rats. *Interdiscip Toxicol*. 2020; Vol. 13(2): 67-72

- [20] Vasileiou C, Befani C, **Dimas K**, Liakos P, Papandreou C. FGF-2 and HGF reverse abiraterone's effect on intracellular levels of DHT in androgen dependent and androgen independent prostate cancer cell lines. *J BUON* 2020; 25(2): 1141-1147.
- [21] Magouliotis DE, Sakellaridis N, **Dimas K**, Tasiopoulou VS, Svokos KA, Svokos AA and Zacharoulis D. In Silico Transcriptomic Analysis of the Chloride Intracellular Channels (CLIC) Interactome Identifies a Molecular Panel of Seven Prognostic Markers in Patients with Pancreatic Ductal Adenocarcinoma. *Current Genomics* 21(2): 119 – 127. DOI: 10.2174/1389202921666200316115631
- [22] Magouliotis DE, Tasiopoulou VS, **Dimas K**, Sakellaridis N, Svokos KA, Svokos AA, Zacharoulis D Transcriptomic analysis of the Aquaporin (AQP) gene family interactome identifies a molecular panel of four prognostic markers in patients with pancreatic ductal adenocarcinoma. *Pancreatol.* 2019 Apr;19(3):436-442. doi: 10.1016/j.pan.2019.02.006. Epub 2019 Feb 11
- [23] Bilalis P, Skoulas D, Karatzas A, Marakis J, Stamogiannos A, Tsimblouli C, Sereti E, Stratikos E, **Dimas K**, Vlassopoulos D, Iatrou H. Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine To Treat Pancreatic Cancer. *Biomacromolecules*. 2018 Sep 10;19(9):3840-3852. doi: 10.1021/acs.biomac.8b00959. Epub 2018 Aug 27.
- [24] Gurel-Gurevin E, Kiyani HT, Esener OBB, Aydinlik S, Uvez A, Ulukaya E, **Dimas K**, Armutak EI. Chloroquine Used in Combination with Chemotherapy Synergistically Suppresses Growth and Angiogenesis In Vitro and In Vivo. *Anticancer Res*. 2018 Jul;38(7):4011-4020
- [25] Milošević Z, Banković J, Dinić J, Tsimblouli C, Sereti E, Dragoj M, Paunović V, Milovanović Z, Stepanović M, Tanić N, **Dimas K**, Pešić M. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. *Cell Oncol (Dordr)*. 2018 Aug;41(4):409-426. doi: 10.1007/s13402-018-0380-x. Epub 2018 May 22
- [26] Kamposioras K, Tsimblouli C, Verbeke C, Anthoney A, Daoukopoulou A, Papandreou CN, Sakellaridis N, Vassilopoulos G, Potamianos SP, Liakouli V, Migneco G, Del Galdo F, **Dimas K**. Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. *Int J Oncol*. 2019 Feb;54(2):537-549. doi: 10.3892/ijo.2018.4640. Epub 2018 Nov 21.
- [27] Cevatemre B, Erkisa M, Aztopal N, Karakas D, Alper P, Tsimblouli C, Sereti E, **Dimas K**, Armutak EI, Gurevin EG, Uvez A, Mori M, Berardozi S, Ingallina C, D'Acquarica I, Botta B, Ozpolat B, Ulukaya E. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autophagy in breast cancer. *Pharmacol Res*. 2017 Dec 1. pii: S1043-6618(17)30993-3.
- [28] Dragoj M, Bankovic J, Sereti E, Stojanov SJ, **Dimas K**, Pesic M, Stankovic T. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors. *Invest New Drugs*. 2017 Jul 22. doi: 10.1007/s10637-017-0494-4. [Epub ahead of print]
- [29] Stagno MJ, Zacharopoulou N, Bochem J, Tsapara A, Pelzl L, Al-Maghout T, Kallergi G, Alkahtani S, Alevizopoulos K, **Dimas K**, Calogeropoulou T, Warmann SW, Lang F, Schmid E, Stournaras C. Istaroxime

- Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells. *Cell Physiol Biochem*. 2017;42(4):1366-1376. doi: 10.1159/000479200. Epub 2017 Jul 14.
- [30] Tsangaris GT, **Dimas K**, Malamou A, Katsafadou A, Papathanasiou C, Stravopodis DJ, Vorgias CE, Gazouli M, Anagnostopoulos AK. Molecular Proteomic Characterization of a Pediatric Medulloblastoma Xenograft. *Cancer Genomics Proteomics*. 2017 Jul-Aug;14(4):267-275.
- [31] Yoon S, Huang KW, Reebye V, Spalding D, Przytycka TM, Wang Y, Swiderski P, Li L, Armstrong B, Reccia I, Zacharoulis D, **Dimas K**, Kusano T, Shively J, Habib N, Rossi JJ. Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. *Mol Ther Nucleic Acids*. 2017 Mar 17; 6: 80-88. doi: 10.1016/j.omtn.2016.
- [32] Ikitimur-Armutak EI, Gurel-Gurevin E, Kiyan HT, Aydinlik S, Yilmaz VT, **Dimas K**, Ulukaya E. Anti-angiogenic effect of a Palladium (II)-Saccharinate Complex of Terpyridine in vitro and in vivo. *Microvasc Res*. 2017 Jan;109: 26-33
- [33] Vaiou M, Pangou E, Liakos P, Sakellaridis N, Vassilopoulos G, Papandreou C, **Dimas K**. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity. *J Cancer Res Clin Oncol*. 2016 Oct;142 (10):2141-58
- [34] Alevizopoulos K, **Dimas K**, Papadopoulou N, Schmidt EM, Tsapara A, Alkahtani S, Honisch S, Prousis KC, Alarifi S, Calogeropoulou T, Lang F, Stournaras C. Functional characterization, and anti-cancer action of the clinical phase II cardiac Na⁺/K⁺ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor. *Oncotarget*. 2016 Mar 24. doi: 10.18632/oncotarget.8329.
- [35] **Dimas K**, Tsimplouli C, Houchen C, Pantazis P, Sakellaridis N, Tsangaris GT, Anastasiadou E, Ramanujam RP. An Ethanol Extract of Hawaiian Turmeric: Extensive In Vitro Anticancer Activity Against Human Colon Cancer Cells. *Altern Ther Health Med*. 2015; 21 Suppl 2:46-54.
- [36] Anagnostopoulos AK, Papathanassiou C, Karamolegou K, Anastasiadou E, **Dimas K**, Kontos H, Koutsopoulos A, Prodromou N, Tzortzatou-Stathopoulou F, Tsangaris GT. Proteomic Studies of Pediatric Medulloblastoma Tumors with 17p Deletion. 2015 Feb 6;14(2): 1076-88.doi: 10.1021/pr501219f
- [37] Moraitis D, Karanikou M, Liakou C, **Dimas K**, Tzimas G, Tseleni-Balafouta S, Patsouris E, Rassidakis GZ, Kouvaraki MA. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas. *Surgery*. 2014 Dec; 156(6):1542-9.
- [38] Honisch S, Alkahtani S, Kounenidakis M, Liu G, Alarifi S, Al-Yahya H, **Dimas K**, Al Kahtane AA, Prousis KC, Al-Dahmash B, Calogeropoulou T, Alevizopoulos K, Lang F, Stournaras C. A steroidal Na⁺/K⁺ ATPase Inhibitor Triggers Pro-Apoptotic Signaling and Induces Apoptosis in Prostate and Lung Tumor Cells. *Anticancer Agents Med Chem*. 2014; 14(8):1161-8.
- [39] Iatrou H, **Dimas K**, Gkikas M, Tsimblouli C, Sofianopoulou S. Polymersomes from Polypeptide Containing Triblock Co- and Terpolymers for Drug Delivery against Pancreatic Cancer: Asymmetry of the External Hydrophilic Blocks. *Macromol Biosci*. 2014 May 19. doi: 10.1002/mabi.201400137. [Epub ahead of print].

- [40] Ulukaya E, Sarimahmut M, Cevatemre B, Ari F, Yerlikaya A, **Dimas K**. Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro. *Biomed Pharmacother*. 2014 May;68(4):477-82.
- [41] Drago L, Boot W, **Dimas K**, Malizos K, Hänsch GM, Stuyck J, Gawlitta D, Romanò CL. Does Implant Coating with Antibacterial-Loaded Hydrogel Reduce Bacterial Colonization and Biofilm Formation in Vitro? *Clin Orthop Relat Res*. 2014 Nov; 472(11):3311-23.
- [42] **Dimas K**, Papadopoulou N, Baskakis C, Prousis KC, Tsakos M, Alkahtani S, Honisch S, Lang F, Calogeropoulou T, Alevizopoulos K, Stournaras C. Steroidal Cardiac Na⁺/K⁺ ATPase Inhibitors Exhibit Strong Anti-Cancer Potential in Vitro and in Prostate and Lung Cancer Xenografts in Vivo. *Anticancer Agents Med Chem*. 2014 Jun; 14(5):762-70.
- [43] Thalassitis A, Katsori AM, **Dimas K**, Hadjipavlou-Litina DJ, Pyleris F, Sakellaridis N, Litinas KE Synthesis and biological evaluation of modified purine homo-N-nucleosides containing pyrazole or 2-pyrazoline moiety. *J Enzyme Inhib Med Chem*. 2014 Feb; 29(1):109-17.
- [44] Riganas S, Papanastasiou I, Foscolos GB, Tsotinis A, Serin G, Mirjolet JF, **Dimas K**, Kourafalos VN, Eleutheriades A, Moutsos VI, Khan H, Georgakopoulou S, Zaniou A, Prassa M, Theodoropoulou M, Mantelas A, Pondiki S, Vamvakides A. New adamantane phenylalkylamines with sigma-receptors binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain. *J Med Chem*. 2012 Nov 26; 55(22):10241-61.
- [45] Tsirmoula S, **Dimas K**, Hatzia Apostolou M, Lamprou M, Ravazoula P, Papadimitriou, E. Implication of pleiotrophin in human PC3 prostate cancer cell growth *in vivo*. *Cancer Sci*. 2012 Oct;103(10):1826-32
- [46] Almeida C, Hemberger Y, Schmitt SM, Bouhired S, Natesan L, Kehraus S, **Dimas K**, Gütschow M, Bringmann G, König GM. Marilines A-C: Novel Phthalimidines from the Sponge-Derived Fungus *Stachylidium* sp. *Chemistry*. 2012 Jul 9;18(28):8827-34
- [47] Riganas S, Papanastasiou I, Foscolos GB, Tsotinis A, **Dimas K**, Kourafalos VN, Eleutheriades A, Moutsos VI, Khan H, Margarita P, Georgakopoulou S, Zaniou A, Theodoropoulou M, Mantelas A, Pondiki S, Vamvakides A. New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity. *Med Chem*. 2012 Jul;8(4):569-86
- [48] Riganas S, Papanastasiou I, Foscolos GB, Tsotinis A, Bourguignon JJ, Serin G, Mirjolet JF, **Dimas K**, Kourafalos VN, Eleutheriades A, Moutsos VI, Khan H, Georgakopoulou S, Zaniou A, Prassa M, Theodoropoulou M, Pondiki S, Vamvakides A. Synthesis, σ_1 , σ_2 -receptors binding affinity and antiproliferative action of new C1-substituted adamantanes. *Bioorg Med Chem*. 2012 May 15;20(10):3323-31
- [49] Thanasopoulou A, Stravopodis DJ, **Dimas KS**, Schwaller J, Anastasiadou E. Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control. *PLoS One*. 2012;7(2):e31007
- [50] Kouvaraki MA, Liakou C, Paraschi A, **Dimas K**, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ, Moraitis D. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. *Surgery*. 2011 Dec;150(6):1258-65

- [51] Kontogiannopoulos KN, Assimopoulou AN, **Dimas K**, Papageorgiou VP. Shikonin-loaded liposomes as a new drug delivery system: physicochemical characterization and *in vitro* cytotoxicity. *Eur. J. Lipid Sci. Technol.* 2011, 113, 1113–1123
- [52] Ulukaya E, Ari F, **Dimas K**, Ikitimur EI, Guney E, Yilmaz VT. Anti-cancer activity of a novel palladium (II) complex on human breast cancer cells in vitro and in vivo. *Eur J Med Chem.* 2011 Oct; 46(10):4957-63.
- [53] Mahaira LG, Tsimplouli C Sakellaridis N, Alevizopoulos K, Demetzos C, Han Z, Pantazis P, **Dimas K**. The labdane diterpene sclareol (labd-14-ene-8, 13-diol) induces apoptosis in human 3 tumor cell lines and suppression of tumor growth in vivo via a p53-independent mechanism of action. *Eur J Pharmacol.* 2011 Sep;666(1-3):173-82
- [54] Ulukaya E, Ari F, **Dimas K**, Sarimahmut M, Guney E, Sakellaridis N, Yilmaz VT. Cell death-inducing effect of novel palladium (II) and platinum (II) complexes on non-small cell lung cancer cells in vitro. *J Cancer Res Clin Oncol.* 2011 Oct; 137(10):1425-34.
- [55] Tsimplouli C, Demetzos C, Hadzopoulou-Cladaras M, Pantazis P, **Dimas K**. In vitro activity of dietary flavonol congeners against human cancer cell lines. *Eur J Nutr.* 2011 May 20.
- [56] Gardikis K, Fessas D, Signorelli M, **Dimas K**, Tsimplouli C, Ionov M, Demetzos C. A new chimeric advanced Drug Delivery nano System (chi-aDDnS) composed of PAMAM G 3.5 dendrimer and liposomes as Doxorubicin's carrier. *In vitro* pharmacological studies. *Journal of Nanoscience and Nanotechnology* 2011, May; 11(5):3764-72.
- [57] Katsori AM, **Dimas K**, Chatzopoulou M, Kontogiorgis C, Patsilinos A, Trangas T, Hadjipavlou-Litina D. Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. *Eur J Med Chem.* 2011 Jul;46(7): 2722-35
-
- [58] Anagnostopoulos AK, **Dimas K**, Papathanassiou C, Braoudaki M, Anastasiadou E, Vougas K, Karamolegou K, Kontos H, Prodromou N, Tzortzatos-Stathopoulou F, Tsangaris GT. Proteomics studies of childhood pilocytic astrocytoma. *J Proteome Res.* 2011 May 6; 10(5):2555-65.
- [59] Pandelidou M, **Dimas K**, Georgopoulos A, Hatziantoniou and Demetzos C. Preparation and Characterization of Lyophilised EGG PC Liposomes incorporating Curcumin and Evaluation of its Activity against Colorectal Cancer Cell Lines. *J Nanosci Nanotechnol.* 2011 Feb; 11(2):1259-66.
- [60] Gardikis K, Tsimplouli C, **Dimas K**, Micha-Screttas M, Demetzos C. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers. *Int J Pharm.* 2010 Dec 15; 402(1-2):231-7.
- [61] Gardikis K, **Dimas K**, Georgopoulos A, Kaditi E, Pispas S and Demetzos C. β -lactam functionalized poly (isoprene-b-ethylene oxide) amphiphilic block copolymer micelles as a new nanocarrier system for curcumin. *Current Nanoscience*, 2010 Jun; 6(3): 277-284.
- [62] Saroglou V, Karioti A, Rancic A, **Dimas K**, Koukoulitsa C, Zervou M, Skaltsa H. Sesquiterpene lactones from *Anthemis melanolepis* and their antibacterial and cytotoxic activities. Prediction of their pharmacokinetic profile. *J Nat Prod.* 2010 Feb 26;73(2):242-6

- [63] Gu S, Papadopoulou N, Gehring EM, Nasir O, **Dimas K**, Bhavsar SK, Föller M, Alevizopoulos K, Lang F, Stournaras C. Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo. *Mol Cancer*. 2009 Dec; 1; 8:114
- [64] Han Z, **Dimas K**, Tian X, Wang Y, Hemmi H, Yamada K, Kato N, Pantazis P, Ramanujam RJ, Anant S, Wyche JH, Houchen CW. 14-3-3 sigma-dependent resistance to cisplatin. *Anticancer Res*. 2009 Jun;29(6):2009-14.
- [65] **Dimas K**, Hatziantoniou S, Wyche JH, Pantazis P. A mastic gum extract induces suppression of growth of human colorectal tumor xenografts in immunodeficient mice. *In Vivo*. 2009 Jan-Feb; 23(1):63-8.
- [66] Lagadinou ED, Ziros P, Tsopra O, **Dimas K**, Thanopoulou E, Kouraklis-Symeonidis A, Karakantza M, Pantazis P, Zoumbos NC. Absence of JNK activation is a predictor of anthracycline resistance in AML. *Leukemia* 2008 Oct;22(10):1899-908.
- [67] **Dimas K**, Tsimplouli C, Anagnostopoulos A, Mahaira L, Iliopoulou E, Perez S, Vougas K and Tsangaris GT. The Proteome Profile of Two Cell Lines and their Xenografts Isolated from a Patient with Clear Cell Sarcoma (Soft Tissue Melanoma). *Cancer Genomics & Proteomics* 2008, 5: 175-238
- [68] **Dimas K**, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P, Demetzos C. Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. *Apoptosis*. 2007 Apr; 12(4):685-94.
- [69] Balan KV, Prince J, Han Z, **Dimas K**, Cladaras M, Wyche JH, Sitaras NM, Pantazis P. Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from *Pistacia lentiscus* L. var. *chia*. *Phytomedicine*. 2007 Apr; 14(4):263-72.
- [70] Tamvakopoulos C, **Dimas K**, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH, Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. *Clin Cancer Res*. 2007 Feb 15; 13(4):1269-77.
- [71] Paradissis A, Hatziantoniou S, Georgopoulos A, Psarra AM, **Dimas K**, Demetzos C. Liposomes modify the subcellular distribution of sclareol uptake by HCT-116 cancer cell lines. *Biomed Pharmacother*. 2007 Feb-Apr; 61(2-3):120-4.
- [72] Matsingou C, **Dimas K**, Demetzos C. Design and development of liposomes incorporating a bioactive labdane-type diterpene. In vitro growth inhibiting and cytotoxic activity against human cancer cell lines. *Biomed Pharmacother*. 2006 May; 60(4):191-9.
- [73] **Dimas K**, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, Demetzos C. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. *Biomed Pharmacother*. 2006 Apr; 60(3):127-33.
- [74] Papagiannaros A, Hatziantoniou S, **Dimas K**, Papaioannou GT, Demetzos C. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. *Biomed Pharmacother*. 2006 Jan; 60(1):36-42.
- [75] Balan KV, Sitaras NM, **Dimas K**, Han Z, Wyche JH, Pantazis P. Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line. *Chemotherapy*. 2006; 52(3):137-46.

- [76] Saroglou V, Karioti A, Demetzos C, **Dimas K**, Skaltsa H. Sesquiterpene lactones from *Centaurea spinosa* and their antibacterial and cytotoxic activities. *J Nat Prod*. 2005 Sep; 68(9):1404-7.
- [77] Papagiannaros A, Hatziantoniou S, Lelong-Rebel IH, Papaioannou GT, **Dimas K**, Demetzos C. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice. *In Vivo*. 2006 Jan-Feb; 20(1):129-35.
- [78] Hatziantoniou S, **Dimas K**, Georgopoulos A, Sotiriadou N, Demetzos C. Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts. *Pharmacol Res*. 2006 Jan; 53(1):80-7.
- [79] Matsingou C, Hatziantoniou S, Georgopoulos A, **Dimas K**, Terzis A, Demetzos C. Labdane-type diterpenes: thermal effects on phospholipid bilayers, incorporation into liposomes and biological activity. *Chem Phys Lipids*. 2005 Dec; 138(1-2):1-11.
- [80] Papagiannaros A, **Dimas K**, Papaioannou GT, Demetzos C. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. *Int J Pharm*. 2005 Sep 30; 302(1-2):29-38.
- [81] Balan KV, Demetzos C, Prince J, **Dimas K**, Cladaras M, Han Z, Wyche JH, Pantazis P. Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum. *In Vivo*. 2005 Jan-Feb; 19(1):93-102.
- [82] Malisiova F, Hatziantoniou S, Kletsas D, **Dimas K**, Demetzos C. Liposomal formulations from phospholipids of Greek almond oil. Properties and biological activity. *Z. Naturforsch, Bioscience* 2004, 59:330-334
- [83] Goniotaki M, Hatziantoniou S, **Dimas K**, Wagner M, Demetzos C. Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell lines. *J Pharm Pharmacol*. 2004 Oct; 56(10):1217-24.
- [84] Pluquet O, North S, Bhoumik A, **Dimas K**, Ronai Z, Hainaut P. The cytoprotective aminothiols WR1065 activates p53 through a non-genotoxic signalling pathway involving c-Jun N-terminal kinase. *J Biol Chem*. 2003 Apr 4; 278(14):11879-87.
- [85] Koukoulitsa E, Skaltsa H, Karioti A, Demetzos C, **Dimas K**. Bioactive sesquiterpene lactones from *Centaurea* species and their cytotoxic/cytostatic activity against human cell lines in vitro. *Planta Med*. 2002 Jul; 68(7):649-52.
- [86] Kolocouris A, **Dimas K**, Pannecouque C, Witvrouw M, Foscolos GB, Stamatiou G, Fytas G, Zoidis G, Kolocouris N, Andrei G, Snoeck R, De Clercq E. New 2-(1-adamantylcarbonyl) pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. *Bioorg Med Chem Lett*. 2002 Mar 11; 12(5):723-7.
- [87] Maswadeh H, Demetzos C, **Dimas K**, Loukas YL, Georgopoulos A, Mavromoustakos T, Papaioannou GT. In-vitro cytotoxic/cytostatic activity of anionic liposomes containing vinblastine against leukaemic human cell lines. *J Pharm Pharmacol*. 2002 Feb; 54(2):189-96.

- [88] Demetzos C, **Dimas K**, Hatziantoniou S, Anastasaki T, Angelopoulou D. Cytotoxic and anti-inflammatory activity of labdane and cis-clerodane type diterpenes. *Planta Med.* 2001 Oct; 67(7):614-8.
- [89] Maswadeh H, Demetzos C, **Dimas K**, Hatziantoniou S, Georgopoulos A, Rallis M, Dallas P, Papaioannou G. Accumulation of vinblastine into transfersomes and liposomes in response to a transmembrane ammonium sulfate gradient and their cytotoxic/cytostatic activity in vitro. *Anticancer Res.* 2001 Jul-Aug; 21(4A):2577-83.
- [90] **Dimas K**, Demetzos C, Vaos V, Ioannidis P, Trangas T. Labdane type diterpenes down-regulate the expression of c-Myc protein, but not of Bcl-2, in human leukemia T-cells undergoing apoptosis. *Leuk Res.* 2001 Jun; 25(6):449-54.
- [91] Angelopoulou D, Demetzos C, **Dimas C**, Perdetzoglou D, Loukis A. Essential oils and hexane extracts from leaves and fruits of *Cistus monspeliensis*. Cytotoxic activity of ent-13-epi-manoyl oxide and its isomers. *Planta Med.* 2001 Mar; 67(2):168-71.
- [92] Maswadeh H, Hatziantoniou S, Demetzos C, **Dimas K**, Georgopoulos A, Rallis M. Encapsulation of vinblastine into new liposome formulations prepared from triticum (wheat germ) lipids and its activity against human leukemic cell lines. *Anticancer Res.* 2000 Nov-Dec; 20(6B):4385-90.
- [93] **Dimas K**, Demetzos C, Angelopoulou D, Kolokouris A, Mavromoustakos T. Biological activity of myricetin and its derivatives against human leukemic cell lines in vitro. *Pharmacol Res.* 2000 Nov; 42(5):475-8.
- [94] **Dimas K**, Demetzos C, Mitaku S, Marselos M, Tzavaras T, Kokkinopoulos D. Cytotoxic activity of kaempferol glycosides against human leukaemic cell lines in vitro. *Pharmacol Res.* 2000 Jan; 41(1):83-86.
- [95] **Dimas K**, Demetzos C, Vaos B, Marselos M, Kokkinopoulos D. Cytotoxic and antiproliferative effects of heptaacetyltiliroside on human leukemic cell lines. *Leuk Res.* 1999 Nov; 23(11):1021-33.
- [96] **Dimas K**, Demetzos C, Mitaku S, Vaos B, Marselos M, Tzavaras T, Kokkinopoulos D. Cytotoxic activity and antiproliferative effects of a new semi-synthetic derivative of Ent-3 beta-hydroxy-13-epi-manoyl oxide on human leukemic cell lines. *Anticancer Res.* 1999 Sep-Oct; 19(5B):4065-72.
- [97] Mitrocotsa D, Bosch S, Mitaku S, **Dimas C**, Skaltsounis AL, Harvala C, Briand G, Roussakis C. Cytotoxicity against human leukemic cell lines, and the activity on the expression of resistance genes of flavonoids from *Platanus orientalis*. *Anticancer Res.* 1999 May-Jun; 19(3A):2085-8.
- [98] **Dimas K**, Kokkinopoulos D, Demetzos C, Vaos B, Marselos M, Malamas M, Tzavaras T. The effect of sclareol on growth and cell cycle progression of human leukemic cell lines. *Leuk Res.* 1999 Mar; 23(3):217-34.
- [99] **Dimas K**, Demetzos C, Marsellos M, Sotiriadou R, Malamas M, Kokkinopoulos D. Cytotoxic activity of labdane type diterpenes against human leukemic cell lines in vitro. *Planta Med.* 1998 Apr; 64(3):208-11.
- [100] Demetzos C, Magiatis P, Typas MA, **Dimas K**, Sotiriadou R, Perez S, Kokkinopoulos D. Biotransformation of the flavonoid tiliroside to 7-methylether tiliroside: bioactivity of this metabolite and of its acetylated derivative. *Cell Mol Life Sci.* 1997 Jul; 53(7):587-92.

[101] Sotiriadou R, Kokkinopoulos D, Stinios J, **Dimas C**, Trangas T, Perez S. delta IK17: an antigen expressed on human lymphocytes. *Int J Biol Markers*. 1996 Oct-Dec; 11(4):183-9.

Άρθρα Ανασκόπησης

- [1] Koutsougianni F, Alexopoulou D, Uvez A, Lamprianidou A, Sereti E, Tsimplouli C, Ilkay Armutak E, Dimas K P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies? *Biochem Pharmacol*. 2023 Apr; 210:115488. doi: 10.1016/j.bcp.2023
- [2] Sereti E, Papapostolou I and **Dimas K**. Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine? *Biomedicines*. 2023 doi: 10.3390/biomedicines11030890.
- [3] Kamposioras K, Vassilakopoulou M, Anthoney A, Bariuso J, Mauri D, Mansoor W, Papadopoulos V, **Dimas K**. Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies. *Pharmacology & Therapeutics, Pharmacol Ther*. 2022 May;233: 108028. doi: 10.1016/j.pharmthera.2021 (Invited)
- [4] Ulukaya E, Karakas D, **Dimas K**. Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients. *Medicina (Kaunas)*. 2021 Jun 19;57(6):636. (Invited)
- [5] Lambrianidou, A., Koutsougianni, F., Papapostolou, I., **Dimas, K**. Recent Advances on the Anticancer Properties of Saffron (*Crocus sativus* L.) and Its Major Constituents. *Molecules (Basel, Switzerland)*, 2020, 26(1) (Invited)
- [6] Liarou E., Varlas S, Skoulas D, Tsimblouli C, Sereti E, **Dimas K**, Iatrou, H. Smart polymersomes and hydrogels from polypeptide-based polymer systems through α -amino acid N-carboxyanhydride ring-opening polymerization. From chemistry to biomedical applications. *Progress in Polymer Science*. Volume 83, August 2018, Pages 28-78 (Invited)
- [7] Gerogianni K, Tsezou A, **Dimas K**. Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. *Mol Diagn Ther*. 2018 Jun;22(3):297-314. doi: 10.1007/s40291-018-0330-3.
- [8] Sereti E, Karagianellou T, Kotsoni I, Magouliotis D, 2, Kamposioras K, Sakellaridis N, Zacharoulis D, **Dimas K**. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging precious allies in the war on a devastating cancer? *J Proteomics*. 2018 Sep 30; 188:107-118. doi: 10.1016/j.jprot.2018.01.012. Epub 2018 Feb 14 (Invited)
- [9] Papadopoulos V, Tsapakidis K, Riobo Del Galdo NA, Papandreou CN, Del Galdo F, Anthoney A, Sakellaridis N, **Dimas K**, Kamposioras K. The Prognostic Significance of the Hedgehog Signaling Pathway in Colorectal Cancer. *Clin Colorectal Cancer*. 2016 Jun;15(2):116-27
- [10] **Dimas KS**, Pantazis P, Ramanujam R. Chios Mastic Gum: A Plant-produced Resin Exhibiting Numerous Diverse Pharmaceutical and Biomedical Properties. *In Vivo*. 2012 Sep;26(5):777-85

Βιβλία/Κεφάλαια σε βιβλία

- 1) Pitsikas N, **Dimas K**. *Crocus sativus* L. Extract and Its Constituents: Chemistry, Pharmacology and Therapeutic Potential.
- 2) Rang and Dale *Φαρμακολογία* 7&8 έκδοση, Επιμέλεια/Μετάφραση, Κεφάλαια 21, 25, 27, 57 &58

- 3) **Dimas K.**, Sereti E and Sakellaridis N. (2018) Kaposi's Sarcoma. Reference Module in Biomedical Sciences. Elsevier 2018 <https://doi.org/10.1016/B978-0-12-801238-3.05106-0>
- 4) **Dimas K.**, Ulukaya E. and Sakellaridis N. (2015) Salivary Gland Tumors. Reference Module in Biomedical Sciences. Elsevier. 12-Jun-15 doi: 10.1016/B978-0-12-801238-3.99478-9.
- 5) **Dimas K.** and Sakellaridis N. (2015) Choriocarcinoma. Reference Module in Biomedical Sciences. Elsevier. 12-Jun-15 doi: 10.1016/B978-0-12-801238-3.99474-1.
- 6) **Dimas K.** and Sakellaridis N. (2015) Kaposi's Sarcoma. Reference Module in Biomedical Sciences. Elsevier. 9-Apr-15 doi: 10.1016/B978-0-12-801238-3.05106-0.
- 7) **Dimas K.**, Ulukaya E. and Sakellaridis N. (2015) Cancer of the Eye (Intraocular Cancer). Reference Module in Biomedical Sciences. Elsevier. 12-Jun-15 doi: 10.1016/B978-0-12-801238-3.99473-X.
- 8) Gardikis K, Mourelatou EA, Ionov M, Aserin A, Libster D, Klajnert B, Bryszewska M, Garti N, Majoral JP, **Dimas K** and Demetzos C. Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applications. Barbara Klajnert, Ling Peng, Valentin Cena (Eds), Dendrimers in Biomedical Applications 2013, Royal Society of Chemistry.
- 9) **Dimas K**, Tsimplouli C, Ramanujam R, Pantazis P, Sakellaridis N. A Tour to the Stars of the Immunodeficient Mice-Galaxy, Leon V. Berhardt (Ed), Advances in Medicine and Biology. Volume 57, Nova Science Publishers, NY, USA 2012
- 10) Tsimplouli C, Pantazis P, Alevizopoulos K, Ulukaya E, **Dimas K**. Patient-Derived Xenografts: Real-Time Modeling of Cancer, Leon V. Berhardt (Ed), Advances in Medicine and Biology, Volume 57, Nova Science Publishers, NY, USA, 2012
- 11) Leondaritis G, Koliou X, Johnson S, Li C, Florakis A, **Dimas K**, Sakellaridis N and Mangoura D. Interplay Between Protein Kinase C Isoforms Alpha and Epsilon, Neurofibromin, and the Ras/MAPK Pathway in Neuroblastoma Differentiation. Neuroblastoma - Present and Future, Hiroyuki Shimada (Ed.), InTech, NY, USA, 2012
- 12) Pantazis P, **Dimas K**, Wyche JH, AnantS, Houchen CW, Panyam J, and Ramanujam RP. Preparation of siRNA-Encapsulated PLGA Nanoparticles for Sustained Release of siRNA and Evaluation of Encapsulation Efficiency. Mikhail Soloviev (ed.), Nanoparticles in Biology and Medicine: Methods and Protocols, Methods in Molecular Biology, vol. 906, Springer Science+Business Media, LLC 2012.
- 13) Paradissis A, Hatziantoniou S, Georgopoulos A, **Dimas K**, and Demetzos C. Uptake Studies of Free and Liposomal Sclareol by MCF-7 and H-460 Human Cancer Cell Lines. Nanomaterials and Nanosystems for Biomedical Applications; Editor M. Reza Mozafari, Massey University, New Zealand, 2007, Springer, the Netherlands.
- 14) Demetzos C, **Dimas K**. Labdane type diterpenes: chemistry and biological activity. *Series of Books 'Studies in Natural Product Chemistry'*; Editor Atta-ur- Rahman, University of Karachi, Karachi, Pakistan vol. 25, 2001 ELSEVIER Ltd.

Διπλώματα Ευρεσιτεχνιών

- 1) GR No 1009114, Linear Pentablock Polypeptidic and Hybrid Polymers to give In Situ Forming Self-Healing pH and Temperature Responsive Hydrogels for Localized Targeted Delivery of Gemcitabine.
- 2) TR 201406644B A palladium complex with high anticancer activity.

National phases:

JP 2017-520525 A 2017.7.27

WO 2015/17095A1

USP application US2017/0106000A1, April 20, 2017

- 3) GR No 1003509, Labdane diterpenes in liposomal form; in vitro studies in human leukaemia cell lines of the new liposomal products.
- 4) US Patent 6652877B1 “Pharmaceutical Formulations Comprising Labdane for the Treatment of Tumors or Leukemias”.

And:

CA 2390553

AU 773462

WO 01/34116

- 5) PCT application (No 990100387/8.11.2000/IPN: WO 01/34116A), “Liposomes composition containing at least one a) labd-13-ene-8a, 15-diol and/or derivatives b) labd-14-ene-8, 13-diol c) 3β-hydroxy-labd-14-ene-8, 13-epoxy and/or derivatives, or a plant extract containing them; pharmaceutical formulation for the treatment of tumors or leukemias”.
- 6) GR No 1004988, Liposomal formulation comprising phospholipids, lipids and a labdane-type diterpene.

Συμμετοχή σε οργανωτικές/επιστημονικές επιτροπές συνεδρίων

1. 6th CONGRESS OF SDIR with international participation “From Collaboration to innovation in Cancer Research” October 2 – 4th 2023, Belgrade, Serbia.
2. 2nd International Multidisciplinary Cancer Research Congress 21-24 July 2022, Giresun-Türkiye.
3. 5th Congress of the Serbian Association of Cancer Research with international participation. October 2021, Belgrade, Serbia.
4. Ηθικοί προβληματισμοί στην έρευνα. 26 Ιουνίου 2021, Βόλος, Ελλάδα.
5. 3rd Congress of the Serbian Association of Cancer Research with international participation. October 2017, Belgrade, Serbia.
6. 6th Multidisciplinary Cancer Research Congress. October 2016, Konya, Turkey.

7. 2nd Congress of the Serbian Association of Cancer Research with international participation. October 2015, Belgrade, Serbia.
8. EACR sponsored -3rd Anticancer Agent Development Congress, May 18-19, Izmir, Turkey.
9. Dendrimers as Composites of Advanced Drug Delivery nano Systems (aDDnSs). Biomedical Applications 4 days Training School, October 3-8, 2011, Athens, COST action TD0802.
10. EACR sponsored - Anticancer Agents Research Congress, October 13-16, 2011, Antalya, Turkey

Διαλέξεις κατόπιν πρόσκλησης

1. A novel rare triple negative breast cancer (TNBC) patient-derived xenograft: Development, characterization, and application 11th IMBMC annual International Medical Congress, November 9th to 11th November 2023, Nicosia Cyprus
2. Αλληλεπιδράσεις αντικαρκινικών φαρμάκων με άλλα σκευάσματα , Ελληνική Ακαδημία Ογκολογίας (ΕΑΚΟ/ΕΟΠΕ), 29 Σεπτεμβρίου-01 Οκτωβρίου 2023
3. Development and characterization of a novel lipid-rich breast cancer patient-derived xenograft (PDX) 2nd International Multidisciplinary Cancer Research Congress 21-24 July 2022, Giresun-Türkiye
4. Αξιολόγηση ερευνητικών προτάσεων. *Ηθικοί προβληματισμοί στην έρευνα. 26 Ιουνίου 2021, Βόλος, Ελλάδα.*
5. Assessment of potential anticancer activity of bioactive compounds using *in vitro* and *in vivo* models. *Marisurf Workshop, 3 December 2020*
6. Mouse models for immunotherapeutic approaches. *1st international multidisciplinary cancer research congress. 18-22 September 2019, Diyarbakir, Turkey.*
7. Heterodimeric interleukin-15 (hetIL-15) alleviates the metastatic burden in a murine model of triple negative breast cancer (TNBC). *NIH, NCI, Center for Cancer Research, Human Retrovirus Section, Vaccine Branch Retreat. 25 June 2019, Frederick, USA.*
8. Sigma Ligands as Potential Novel Targeted Anticancer Therapies. *5th International Multithematic Biomedical Scientific Congress-Nicosia Cyprus (IMBMC 2017)*
9. Mouse models of Cancer: from basic cancer biology studies to precision medicine. *3rd Congress of the Serbian Association of Cancer Research with international participation. October 2017, Belgrade, Serbia*
10. Sigma ligands as targeted anticancer therapeutics. *6th Multidisciplinary Cancer Research Congress. October 2016, Konya, Turkey*
11. Chemosensitivity-Chemoresistance: development, study, and efficacy testing procedure of anticancer drugs. *Hellenic Society for Nanotechnology in Health Sciences (HSnanoHS), Democritus Institute, Athens, Greece.*
12. Sigma receptors as targets for the development of novel targeted anticancer therapies. *2nd Congress of the Serbian Association of Cancer Research with international participation. October 2015, Belgrade, Serbia*
13. Targeting s6 kinases for the development of novel anticancer therapies. *EACR sponsored -3rd Anticancer Agent Development Congress, May 18-19, Izmir, Turkey.*

14. Anticancer targeted therapies. *10th Conference of the Society of Clinical Oncology of Western Greece. 2015 Patras, Greece.*
15. Targeted therapies in Cancer. *8th Conference of the Society for the Study of Metastatic Liver Disease. 2015 Volos Greece.*
16. Anticancer drugs-Targeted therapies. *Seminars in Cancer Biology. June 2014, BRFAA, Athens, Greece (sponsored by JANSSEN-CILAG).*
17. Anticancer efficacy testing using the NCI approach: *EACR-sponsored "2nd Anticancer Agents Congress: Targeting Cancer Stem Cell". 21-24th November 2013, Antalya, Turkey.*
18. Chemosensitivity-Chemoresistance: *Anticancer drugs' development, study, and efficacy testing procedure. 2013, Dept of Chemistry, NKUOA, Athens, Greece.*
19. Kaempferol Glycosides: *Emerging Stars in the Flavonoid Galaxy? IV International Congress of Molecular Medicine, 27-30 June 2012, Istanbul, Turkey.*
20. In vitro anticancer screening assays: theory and applications on drug delivery systems. *Dendrimers as Composites of Advanced Drug Delivery nano Systems (aDDnSs). Biomedical Applications 4 days Training School, October 3-8, 2011, Athens, COST action TD0802.*
21. Labdanes as potential novel chemotherapeutics for cancer. *EACR - Anticancer Agents Research Congress, October 13-16, 2011, Antalya, Turkey.*
22. p90 ribosomal S6 kinases: Potential new targets for promising anticancer therapies? *8th international conference of anticancer research, October 17-22, 2008 Kos, Greece.*

Μέλος σε επιστημονικές εταιρίες

1. Greek Society for Basic and Clinical Pharmacology
2. European Association for Clinical Pharmacology and Therapeutics (EACPT)
3. Hellenic Society for Molecular Cancer Research (HAMCR)
4. European Association for Cancer Research (EACR) (Ambassador for Greece)
5. Institute of Molecular Medicine & Biomedical Research, Greece (Assisting Member)
6. Hellenic Society for Nanotechnology in Health Sciences (Founding member)

Χρηματοδοτήσεις

- ΕΛΙΔΕΚ «Χρηματοδότηση της Βασικής Έρευνας (Οριζόντια υποστήριξη όλων των Επιστημών), Εθνικό Σχέδιο Ανάκαμψης και Ανθεκτικότητας (Ελλάδα 2.0)», Πρόγραμμα: Καινοτόμες νανοδομές για τη στόχευση των Σίγμα 2 υποδοχέων για τη θεραπεία του Παγκρεατικού Καρκίνου **NANOSIGMA 400000€ (ΠΘ 260000€)** (Ρόλος ΕΥ)
- Μελέτη της αντικαρκινικής δράσης μικρών μορίων-ATTICA SCIENCES **12000€** (Ρόλος: ΕΥ)
- ECDC: «Assessing the Risk of Fungal and Parasitic Diseases Transmission by Substances of Human Origin» (Role: Expert)

- Δράση ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ 2017, Κωδικός Τ1ΕΔΚ-01833 (DEMO ΑΕΒΕ, Συνολικός ΠΥ 610894€) **197278,91€** (Ρόλος: ΕΥ για το ΠΘ)
- Δράση ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ 2017, Κωδικός Τ1ΕΔΚ-01612 (Τμήμα Χημείας ΕΚΠΑ, Συνολικός ΠΥ 681760€) *ΕΥ για το ΠΘ* **154291,40€** (Ρόλος: ΕΥ για το ΠΘ)
- Ο ρόλος της caveolin-1 στην ανάπτυξη χημειο-αντοχής στον καρκίνο του παγκρέατος-ΕΟΠΕ **4000€** (Ρόλος: ΕΥ)
- Έλεγχος τοξικότητας ενέσιμων σκευασμάτων -DEMO ΑΕΒΕ (Ρόλος: ΕΥ) **6900€ (2017)/1500€ (2014)**
- Διερεύνηση της στόχευσης της λειτουργίας του mTOR για την ανάπτυξη νέων προσεγγίσεων αντιμετώπισης των επιθετικών μορφών καρκίνου του θυρεοειδούς -ΕΕ/ΠΘ (Ρόλος: ΕΥ) **7500€**
- Μελέτη αντικαρκινικής δράσης μικρών χημικών μορίων σε ζωικά προ-κλινικά μοντέλα καρκίνου (Ρόλος: ΕΥ) **1500€**
- Δωρεά εξοπλισμού από το ίδρυμα «Μποδοσάκης» (1 upright -80°C deep freezer)
- Δωρεά εξοπλισμού από το Νοσ. Ο «Άγιος Σάββας» (1 FACSCalibur, 2 Laminar flow hoods, 2 CO₂ Incubators, 1 Zeiss upright microscope)
- COST-CM1407 “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery”
- COST-CM1106 “Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells”
- Αριστεία 2011-PANNANOMED (Ρόλος: *Επιστημονικός Υπεύθυνος για τα πακέτα εργασίας 6 και 7*- Κύριος Ερευνητής: Ερμής Ιατρού, Αναπληρωτής Καθηγητής, Τμήμα Χημείας, ΕΚΠΑ) **150000€**
- Επιχορήγηση από την εταιρεία Medexis SA (Ρόλος: *Κύριος Ερευνητής*) (Study of the anticancer activity of small molecules against animal cancer models) **5000€**
- -COST-TD0802 “Dendrimers in Biomedical applications” (Ρόλος: *Συμμετέχων-Αναπληρωματικός Εθνικός Εκπρόσωπος στην Επιτροπή Διαχείρισης*)
- -Επιχορήγηση από την εταιρία Anavex SA «Novel σ-receptor ligands with potent antitumor activities» **35000€ plus a post doc compensated directly by the company** (Ρόλος: *Κύριος Ερευνητής*)-
Επιχορήγηση από την εταιρία Γερολυμάτος ΠΙΝ για το πρόγραμμα “Gerolab” (Pharmaceutical formulations comprising labdane for the treatment of tumors or leukemias). Ρόλος: *Συνεργαζόμενος Ερευνητής* - Κύριος Ερευνητής: Κωνσταντίνος Δεμέτζος, Καθηγητής, Τμήμα Φαρμακευτικής, ΕΚΠΑ)- **(2001-2003:100.000.000δρχ, 2002-2005:90.000.000δρχ, 2004-2005:40,000€, 2006-2007:64000€)**